Free Trial
Joseph Thome

Joseph Thome Analyst Performance

Managing Director, Senior Biotechnology Equity Research at TD Cowen

Joseph Thome is a stock analyst at TD Cowen focused in the medical sector, covering 7 publicly traded companies. Over the past year, Joseph Thome has issued 12 stock ratings, including strong buy, buy, and hold recommendations. While full access to Joseph Thome's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Joseph Thome's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
14 Last 5 Years
Buy Recommendations
71.43% 10 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy7.1%1 ratings
Buy64.3%9 ratings
Hold28.6%4 ratings
Sell0.0%0 ratings

Out of 14 total stock ratings issued by Joseph Thome at TD Cowen, the majority (64.3%) have been Buy recommendations, followed by 28.6% Hold and 7.1% Strong Buy.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
7 companies

Joseph Thome, an analyst at TD Cowen, currently covers 7 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
6 companies
85.7%
Manufacturing
1 company
14.3%

Joseph Thome of TD Cowen specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
3 companies
42.9%
MED - DRUGS
2 companies
28.6%
Miscellaneous
1 company
14.3%
PHARMACEUTICAL PREPARATIONS
1 company
14.3%

Joseph Thome's Ratings History at TD Cowen

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Maplight Therapeutics, Inc. stock logo
MPLT
Maplight Therapeutics
4/7/2026Initiated Coverage$22.61Buy
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
3/30/2026Boost Price Target$592.66$660.00Buy
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
3/27/2026Boost Price Target$89.56$125.00Buy
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
2/26/2026Boost Price Target$93.02$117.00Buy
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
2/25/2026Boost Price Target$535.10$575.00Buy
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
1/29/2026Reiterated Rating$77.23Hold
Ardelyx, Inc. stock logo
ARDX
Ardelyx
1/29/2026Reiterated Rating$7.78Buy
PTC Therapeutics, Inc. stock logo
PTCT
PTC Therapeutics
11/5/2025Boost Price Target$71.00$63.00Hold
Ardelyx, Inc. stock logo
ARDX
Ardelyx
10/31/2025Boost Price Target$6.06$10.00Buy
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
9/25/2025Upgrade$73.57Strong-Buy
Mirum Pharmaceuticals, Inc. stock logo
MIRM
Mirum Pharmaceuticals
9/24/2025Initiated Coverage$73.62$95.00Buy
Bright Minds Biosciences Inc. stock logo
DRUG
Bright Minds Biosciences
5/13/2025Initiated Coverage$33.88Buy